Document:

Form of Registrant's Minimum Return Equity

 THIS NOTE IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME
OF A DEPOSITORY OR A NOMINEE OF A DEPOSITORY. THIS NOTE IS NOT EXCHANGEABLE FOR NOTES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND NO TRANSFER OF
THIS NOTE (OTHER THAN A TRANSFER OF THIS NOTE AS A WHOLE BY THE DEPOSITORY TO A NOMINEE OF THE DEPOSITORY OR BY A NOMINEE OF THE DEPOSITORY TO THE DEPOSITORY OR ANOTHER NOMINEE OF THE DEPOSITORY) MAY BE REGISTERED EXCEPT IN THE LIMITED CIRCUMSTANCES
DESCRIBED IN THE INDENTURE. 
 Unless this Note is presented by an authorized representative of The Depository Trust Company, a New York corporation (55
Water Street, New York, New York) (“DTC”), to the Corporation or its agent for registration of transfer, exchange or payment, and this Note is registered in the name of Cede & Co. or such other name as requested by an authorized
representative of DTC, and unless any payment is made to Cede & Co., ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL since the registered owner hereof, Cede & Co., has an interest
herein. 
 THIS NOTE IS NOT A SAVINGS ACCOUNT OR A DEPOSIT, IS NOT AN OBLIGATION OF OR GUARANTEED BY ANY BANKING OR NONBANKING AFFILIATE OF BANK OF AMERICA
CORPORATION, AND IS NOT INSURED BY THE FEDERAL DEPOSIT INSURANCE CORPORATION OR ANY OTHER GOVERNMENTAL AGENCY. 
  

			
	 REGISTERED
	  	$ 3,500,000
		
	 NUMBER     I-            
	  	CUSIP 06050 MGE1

 BANK OF AMERICA CORPORATION 
 MEDIUM-TERM SENIOR NOTE, SERIES K 
 (Indexed Note) 
  

	 ̈	SEE THE ATTACHED PRINCIPAL REPAYMENT AMOUNT RIDER for a description of the PRINCIPAL REPAYMENT AMOUNT and its method of calculation. 

  

	x	SEE THE ATTACHED SUPPLEMENTAL REDEMPTION AMOUNT RIDER for a description of the SUPPLEMENTAL REDEMPTION AMOUNT and its method of calculation 

  

	ORIGINAL	ISSUE DATE: October 26, 2006 

	MATURITY	DATE: October 28, 2011 

	CALCULATION	AGENT: Banc of America Securities LLC (“BAS”) 

	ADDITIONAL	TERMS: See Supplemental Redemption Amount Rider 

	MINIMUM	DENOMINATIONS: $1,000 and whole multiples of $1,000. 

 BANK OF AMERICA CORPORATION, a Delaware corporation (the “Corporation,” which term includes any successor corporation under the Indenture referred to on the reverse hereof), for value received, hereby promises to pay on the
Maturity Date to CEDE & CO., as nominee for The Depository Trust Company, or its registered assigns, (i) the principal amount of THREE MILLION FIVE HUNDRED THOUSAND DOLLARS ($3,500,000) and (ii) that supplemental redemption amount
(the “Supplemental Redemption Amount”) calculated according to the terms of the attached Supplemental Redemption Amount Rider. 
 Any principal or Supplemental Redemption Amount not punctually paid or duly provided for shall be payable as provided in the Indenture. As used in this Note, “business day” means any weekday that is not a legal holiday in New
York, New York, Charlotte, North Carolina, or any other place of payment of this Note, and that is not a date on which banking institutions in those cities or any other place of payment with respect to this Note are authorized or required by law or
regulation to be closed; but that is not a day on which the principal securities market (or markets) on which the constituent stocks of the AMEX Biotechnology Index, are traded is closed. 

 The principal and Supplemental Redemption Amount on this Note are payable in immediately available funds
in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts at the office or agency of the Corporation designated as provided in the Indenture; provided,
however, that the principal or Supplemental Redemption Amount may be paid, at the option of the Corporation, by check mailed to the person entitled thereto at his address last appearing on the registry books of the Corporation relating to the
Notes. Notwithstanding the preceding sentence, payments of the principal and Supplemental Redemption Amount payable on the Maturity Date will be made by wire transfer of immediately available funds to a designated account maintained in the United
States upon (i) receipt of written notice by the Issuing and Paying Agent (as described on the reverse hereof) from the registered holder of this Note not less than one business day prior to the due date of such principal and
(ii) presentation of this Note to The Bank of New York, as Issuing and Paying Agent, 101 Barclay Street, New York, New York 10286 (the “Corporate Trust Office”). 
 For both this Note and Notes issued in certificated form, the payment of principal of and any other amounts due on or after the Maturity Date will be
made only upon the presentation and surrender of such Note at the office of the Trustee or successor thereof, and with respect to this Note, in accordance with the procedures of DTC. 
 References herein to “U.S. dollars,” “U.S.$,” or “$” are to the coin or currency of the United States at the time of
payment is legal tender for the payment of public and private debts. 
 Reference is hereby made to the further provisions of this Note set
forth on the reverse hereof and on the attached Rider, which shall have the same effect as though fully set forth at this place. 
 Unless
the certificate of authentication hereon has been executed by the Trustee or an authenticating agent on behalf of the Trustee by manual signature, this Note shall not be entitled to any benefit under the Indenture or be valid or obligatory for any
purpose. 
  

 2 

 IN WITNESS WHEREOF, the Corporation has caused this Note to be duly executed, by manual or facsimile
signature, under its corporate seal or a facsimile thereof. 
  

							
		 		 	BANK OF AMERICA CORPORATION
				
		 		 	By:	 	  

	[SEAL]	 	Title:	 	Senior Vice President
	ATTEST:	 		 	
				
	By:	 	  
	 		 	
	Title:	 	Assistant Secretary	 		 	

  

 3 

 Certificate of Authentication 
 This is one of the Securities of the series designated therein referred to in the within-mentioned Indenture. 
 Dated: October 26, 2006 
  

			
	 THE BANK OF NEW YORK,
 as
Trustee

		
	By:	 	  

		 	Authorized Signatory

  

 4 

 [Reverse of Note] 
 BANK OF AMERICA CORPORATION 
 MEDIUM-TERM SENIOR NOTE, SERIES K 
 (Indexed Note) 
 SECTION 1. General.
This Note is one of a duly authorized series of Securities of the Corporation unlimited in aggregate principal amount (herein called the “Notes”) issued and to be issued under an Indenture dated as of January 1, 1995 (herein called
the “Indenture”), between the Corporation (successor in interest to NationsBank Corporation) and The Bank of New York, as Trustee (successor in interest to U.S. Bank Trust National Association, successor trustee to BankAmerica National
Trust Company, herein called the “Trustee,” which term includes any successor trustee under the Indenture), as supplemented by a First Supplemental Indenture dated as of September 18, 1998, a Second Supplemental Indenture dated as of
May 7, 2001, a Third Supplemental Indenture dated as of July 28, 2004, and a Fourth Supplemental Indenture dated April 28, 2006, to which Indenture and all indentures supplemental thereto reference is hereby made for a statement of
the respective rights thereunder of the Corporation, the Trustee, and the holders of the Notes, and the terms upon which the Notes are, and are to be, authenticated and delivered. This Note is also one of the Notes designated as the
Corporation’s Senior Medium-Term Notes, Series K, initially limited in aggregate principal amount to $10,000,000,000. The Trustee initially shall act as Security Registrar, Transfer Agent, and Issuing and Paying Agent in connection with the
Notes. The Notes may bear different dates, mature at different times, bear interest at different rates, and vary in such other ways as are provided in the Indenture. 
 SECTION 2. No Sinking Fund. This Note is not subject to any sinking fund. 
 SECTION 3.
Redemption. This Note is not redeemable prior to the Maturity Date. 
 SECTION 5. Defeasance. The provisions of Article
Fourteen of the Indenture do not apply to Securities of this Series. 
 SECTION 6. Events of Default. If an Event of Default (defined
in the Indenture as (a) the Corporation’s failure to pay the principal of (or premium, if any, on) the Notes; (b) the Corporation’s failure to pay interest on the Notes within 30 calendar days after the same becomes due;
(c) the Corporation’s breach of its other covenants contained in this Note or in the Indenture, which breach is not cured within 90 calendar days after written notice by the Trustee or the holders of at least 25% in outstanding principal
amount of all Securities issued under the Indenture and affected thereby; and (d) certain events involving the bankruptcy, insolvency or liquidation of the Corporation) shall occur with respect to the Notes, the principal of all the Notes may
be declared due and payable in the manner and with the effect provided in the Indenture. 
 SECTION 7. Modifications and Waivers. The
Indenture permits, with certain exceptions as therein provided, the amendment of the Indenture and the modification of the rights and obligations of the Corporation and the rights of the holders of the Notes under the Indenture at any time by the
Corporation with the consent of the holders of not less than 66 2/3% in aggregate principal amount of the Notes then outstanding and all other Securities then outstanding under 

  

 5 

 
the Indenture and affected by such amendment and modification. The Indenture also contains provisions permitting the holders of a majority in aggregate
principal amount of the Notes then outstanding and all other Securities then outstanding under the Indenture and affected thereby, on behalf of the holders of all such Securities, to waive compliance by the Corporation with certain provisions of the
Indenture and certain past defaults under the Indenture and their consequences. Any such consent or waiver by the holder of this Note shall be conclusive and binding upon such holder and upon all future holders of this Note and of any Note issued
upon the registration of transfer hereof or in exchange herefor or in lieu hereof whether or not notation of such consent or waiver is made upon this Note. 
 No recourse shall be had for the payment of the principal of, premium on (if any), or other amounts payable on this Note, or for any claim based hereon, or otherwise in respect hereof, or based on or in respect of the
Indenture or any indenture supplemental thereto, against any incorporator, stockholder, officer, or director, as such, past, present, or future, of the Corporation or any predecessor or successor corporation, whether by virtue of any constitution,
statute or rule of law, or by the enforcement of any assessment or penalty or otherwise, all such liability being, by the acceptance hereof and as part of the consideration for issue hereof, expressly waived and released. 
 SECTION 8. Obligations Unconditional. No reference herein to the Indenture and no provision of this Note or of the Indenture shall alter or impair
the obligation of the Corporation, which is absolute and unconditional, to pay the principal of, premium (if any), and other amounts payable on this Note at the times, place and rate, and in the coin or currency, herein prescribed. 
 SECTION 9. Authorized Denominations. The Notes are issuable only as registered Notes without coupons, and unless otherwise set forth above, only
in denominations of $1,000 and whole multiples of $1,000. As provided in the Indenture, and subject to certain limitations therein set forth, Notes are exchangeable for a like aggregate principal amount of Notes of different authorized
denominations, as requested by the holder surrendering the same. 
 SECTION 10. Registration of Transfer. As provided in the Indenture
and subject to certain limitations as therein set forth, the transfer of this Note is registrable in the register maintained by the Registrar, upon surrender of this Note for registration of transfer at the office or agency of the Corporation
designated by it pursuant to the Indenture, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Corporation and the Trustee or the Security Registrar requiring such written instrument of transfer duly
executed by, the registered holder hereof or his attorney duly authorized in writing, and thereupon one or more new Notes of this series, of authorized denominations and for the same aggregate principal amount, will be issued to the designated
transferee or transferees. 
 This Note is being issued by means of a book-entry system with no physical distribution of certificates to be
made except as provided in the Indenture. The book-entry system maintained by DTC will evidence ownership of the Notes, with transfers of ownership effected on the records of DTC and its participants pursuant to rules and procedures established by
DTC and its participants. The Corporation will recognize Cede & Co., as nominee of DTC, while the registered holder of the Notes, as the owner of the Notes for all purposes, including payment of principal and the Supplemental Redemption
Amount, notices and voting. Transfer of principal 

  

 6 

 
and the Supplemental Redemption Amount to participants of DTC will be the responsibility of DTC, and transfer of principal and the Supplemental Redemption
Amount payable to beneficial owners of the Notes by participants of DTC will be the responsibility of such participants and other nominees of such beneficial owners. So long as the book-entry system is in effect, the selection of any Notes to be
redeemed will be determined by DTC pursuant to rules and procedures established by DTC and its participants. The Corporation will not be responsible or liable for such transfers or payments or for maintaining, supervising or reviewing the records
maintained by DTC, its participants, or persons acting through such participants. 
 This Note may be exchanged in whole, but not in part,
for security-printed certificated Notes, only if (i) DTC notifies the Corporation or the Trustee that it is unwilling or unable to continue to act as depository for this Note in global form or if at any time DTC ceases to be a clearing agency
registered under the Securities Exchange Act of 1934, as amended, and in either such case, a successor depository is not appointed by the Corporation within 60 calendar days, or (ii) the Corporation executes and delivers to the Trustee a
written notification that this Note in global form shall be so exchangeable, or (iii) an Event of Default occurs and is continuing with respect to this Note in global form. In any such instance, an owner of a beneficial interest in this Note
will be entitled to physical delivery in certificated form of Notes equal in principal amount to such beneficial interest and to have such Notes registered in its name. Unless otherwise set forth above, Notes so issued in certificated form will be
issued in authorized denominations only and will be issued in registered form only, without coupons. 
 No service charge shall be made for
any such registration of transfer or exchange, but the Corporation may require payment of a sum sufficient to cover any tax, assessment, or other governmental charge, including, without limitation, any withholding tax, payable in connection
therewith. 
 Prior to due presentment of this Note for registration of transfer, the Corporation, the Trustee, the Issuing and Paying Agent,
and any agent of the Corporation, the Trustee or any Issuing and Paying Agent may treat the person in whose name this Note is registered as the owner hereof for all purposes. 
 SECTION 11. Defined Terms. All terms used in this Note which are not defined herein but are defined in the Indenture shall have the meanings
assigned to them in the Indenture. 
 SECTION 12. Governing Law. THIS NOTE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE
LAWS OF THE STATE OF NEW YORK, WITHOUT GIVING EFFECT TO PRINCIPLES OF CONFLICTS OF LAWS. 
  

 7 

 ABBREVIATIONS 
 The following abbreviations, when used in the inscription on the face of the within Note, shall be construed as though they were written out in full according to applicable laws or regulations: 
  

			
	TEN COM--	 	as tenants in common
	TEN ENT--	 	as tenants by the entireties
	JT TEN--	 	as joint tenants with right of survivorship and not as tenants in common

 UNIF GIFT MIN
ACT--                                       
  as Custodian for
                                        

                                        
                 (Cust)
                                        
                (Minor) 
  

					
		 	Under Uniform Gifts to Minors Act	 	
		 	  
	 	
		 	(State)	 	

 Additional abbreviations may also be used though not in the above list. 
  

					
		 	  
	 	
		 	ASSIGNMENT	 	

 FOR VALUE RECEIVED, the undersigned hereby sell(s), assign(s) and transfer(s) unto 
 [PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS 
 INCLUDING ZIP CODE OF ASSIGNEE] 
 ________________________________________________________________________________________________________________________________________________ 
 ________________________________________________________________________________________________________________________________________________ 
 ________________________________________________________________________________________________________________________________________________ 
 Please Insert Social Security or Other 
 Identifying Number of Assignee:
                                        
                     
 the within Note and all rights
thereunder, hereby irrevocably constituting and appointing
                                        
                     Attorney to transfer said Note on the books of the Corporation, with full power of substitution in the premises. 

 

							
	Dated:	 	  
	 		 	  

 NOTICE: The signature to this assignment must correspond with the name as it appears upon the face of the within
Note in every particular, without alteration or enlargement or any change whatever and must be guaranteed. 
  

 8 

 BANK OF AMERICA CORPORATION 
 Medium-Term Senior Note, Series K 
 SUPPLEMENTAL REDEMPTION AMOUNT RIDER

 General 
 This Note is part of a
series of medium-term notes entitled “Medium-Term Notes, Series K” issued under the Indenture, as described in the Prospectus dated April 14, 2004 and Prospectus Supplement dated April 15, 2004 and is designated as the Bank
of America Corporation Minimum Return Equity Appreciation Growth LinkEd Securities “Index EAGLES®,” due October 28, 2011, Linked to the AMEX Biotechnology Index. Certain capitalized terms used herein have the meanings ascribed to them in the Prospectus and the Prospectus Supplement. 
 Payment at Maturity; Supplemental Redemption Amount 
 At maturity, the holder of the Note will receive the principal amount of this Note. The holder of the Note also will receive the Supplemental Redemption Amount, which will not be less than 5.00% of the principal amount of this Note at
maturity. This minimum amount is called the “Minimum Supplemental Redemption Amount.” The Supplemental Redemption Amount will be based primarily upon the performance of the AMEX Biotechnology Index during the term of this Note and will be
determined by the Calculation Agent in the manner described below. 
 The Calculation Agent will determine the Supplemental Redemption Amount
payable to the holder of the Note at maturity by reference to the periodic returns of the AMEX Biotechnology Index during the following 20 “Reference Periods”: 
  

									
	2006/07	 	2007/08	 	2008/09	 	2009/10	 	2010/11
					
	10/23/06-1/23/07	 	10/23/07-1/23/08	 	10/23/08-1/23/09	 	10/23/09-1/23/10	 	10/23/10-1/23/11
					
	1/23/07-4/23/07	 	1/23/08-4/23/08	 	1/23/09-4/23/09	 	1/23/10-4/23/10	 	1/23/11-4/23/11
					
	4/23/07-7/23/07	 	4/23/08-7/23/08	 	4/23/09-7/23/09	 	4/23/10-7/23/10	 	4/23/11-7/23/11
					
	7/23/07-10/23/07	 	7/23/08-10/23/08	 	7/23/09-10/23/09	 	7/23/10-10/23/10	 	7/23/11-10/23/11

 This Note was priced on October 23, 2006, or the “pricing date.” The pricing date
is the first day of the first Reference Period. 
 The last day of each Reference Period is referred to as a “Reset Date.” On each
Reset Date, the Calculation Agent will determine the “Periodic Return” of the AMEX Biotechnology Index for the Reference Period then ended by applying the following formula: 
  

 9 

 (Ending Level - Starting Level) 
 Starting Level 
 The result will be rounded to the nearest ten-thousandth of a decimal
place and then expressed as a percentage. 
 The “Starting Level” for the initial Reference Period is the closing level of the AMEX
Biotechnology Index on the pricing date, or 738.91, and the “Starting Level” for each subsequent Reference Period is the Ending Level for the immediately preceding Reference Period. The “Ending Level” for each Reference Period is
the closing level of the AMEX Biotechnology Index on the applicable Reset Date, or if that day is not a business day (as defined above), the closing level of the AMEX Biotechnology Index on the next following business day. 
 On the pricing date, the Corporation set a cap of 7.00%, or the “Return Cap,” which limits any increases in the Periodic Return of the AMEX
Biotechnology Index to that rate. For any Reference Period in which the Periodic Return is greater than the Return Cap, the Periodic Return for that Reference Period will be deemed to be the Return Cap. 
 After the close of the market on the last Reset Date, the Calculation Agent will determine the Supplemental Redemption Amount, which will not be less
than the Minimum Supplemental Redemption Amount, based on the following formula: 
 Principal Amount x Index Return 
 The “Index Return” is the compounded value of the 20 Periodic Returns computed in the following manner: 
 [The product of (1.00 + the Periodic Return) for each Reference Period] - 1.00 
 The Index Return will be rounded to the nearest ten-thousandth and then expressed as a percentage. 
 The Supplemental Redemption Amount will be calculated after the close of the market on the last Reset Date. The period of time between the last Reset
Date and the Maturity Date is not part of a Reference Period, and, therefore, changes in the AMEX Biotechnology Index during that period will not affect the Supplemental Redemption Amount payable to the holder of this Note at maturity. If the
calculation of the Supplemental Redemption Amount results in an amount that is less than the Minimum Supplemental Redemption Amount, then the Corporation will pay the holder of this Note a Supplemental Redemption Amount equal to the Minimum
Supplemental Redemption Amount. 
 Event of Default 
 Upon the occurrence of an Event of Default (as defined in the Indenture), the holder of this Note only will be entitled to receive the principal amount of the Note, and will not be entitled to payment of the
Supplemental Redemption Amount. 
  

 10 

 Market Disruption 
 Each of the following will be a “Market Disruption Event” if, in the sole opinion of the Calculation Agent, that event materially affects the AMEX Biotechnology Index: 
 (a) the suspension, material limitation, or absence of the trading of a material number of stocks included in the AMEX Biotechnology Index; 

(b) the suspension or material limitation of the trading of stocks on one or more stock exchanges on which stocks included in the AMEX Biotechnology
Index are quoted; 
 (c) a breakdown or failure in the price and trade reporting systems of the respective primary markets on which the
stocks included in the AMEX Biotechnology Index are quoted, as a result of which the reported trading prices for the affected stocks, during the last one-half hour before the close of trading in that market are materially inaccurate; or 

(d) the suspension or material limitation of the trading of (1) options or futures relating to the AMEX Biotechnology Index on any options or
futures exchanges or (2) options or futures generally. 
 For purposes of determining whether a Market Disruption Event has occurred:

 (a) a limitation on the number of hours or days of trading will not be a Market Disruption Event if it results from an announced change in
the regular business hours of the relevant exchange; 
 (b) a limitation on trading imposed by reason of the movements in price exceeding the
levels permitted by any relevant exchange will be a Market Disruption Event; 
 (c) a decision to permanently discontinue trading in the
relevant futures or options contracts will not constitute a Market Disruption Event; and 
 (d) an absence of trading on an exchange or
quotation system will not include any time when that exchange or quotation system is closed for trading under ordinary circumstances. 
 If a
Market Disruption Event occurs or is continuing on a day that would otherwise be a Reset Date, then the Calculation Agent instead will use the closing level of the AMEX Biotechnology Index on the first business day after that day on which no Market
Disruption Event occurs or is continuing. In no event, however, will any Reset Date be postponed by more than five business days. If any Reset Date is postponed to the last possible day, but a Market Disruption Event occurs or is continuing on that
day, that day nevertheless will be the Reset Date, and the Calculation Agent will make a good faith estimate of the closing level of the AMEX Biotechnology Index based upon its assessment of the level of the AMEX Biotechnology Index at that time. If
the last scheduled Reset Date is postponed due to a Market Disruption Event, the Maturity Date for this Note also will be postponed by the same number of business days. 
  

 11 

 Discontinuance of the AMEX Biotechnology Index; Alteration of Method of Calculation 
 If the American Stock Exchange LLC (the “AMEX”) discontinues publication of the AMEX Biotechnology Index and the AMEX or another entity
publishes a successor or substitute index that the Calculation Agent determines, in its sole discretion, is comparable to the discontinued AMEX Biotechnology Index (the new index being referred to as a “Successor Index”), then the relevant
closing levels shall be determined by reference to the Successor Index at the close of trading on the New York Stock Exchange, the AMEX, The Nasdaq National Market, or the relevant exchange or market for the constituent stocks of the Successor
Index. 
 If the Calculation Agent selects a Successor Index, the Calculation Agent immediately shall notify the Corporation and the Trustee,
and the Trustee will provide written notice of a change to the holders of this Note within three business days of selection. 
 If the AMEX
discontinues publication of the AMEX Biotechnology Index, and the Calculation Agent determines that no Successor Index is available, then the Calculation Agent will notify the Corporation and the Trustee and shall calculate the appropriate closing
levels. These calculations by the Calculation Agent will be in accordance with the formula for and method of calculating the AMEX Biotechnology Index last in effect prior to that discontinuance. If a Successor Index is selected or the Calculation
Agent calculates a level as a substitute for the AMEX Biotechnology Index, that Successor Index or level will be substituted for the AMEX Biotechnology Index for all purposes. 
 If at any time the method of calculating the AMEX Biotechnology Index or a Successor Index, or the level of that index, is changed in a material respect,
or if the AMEX Biotechnology Index or a Successor Index in any other way is modified so that it does not, in the opinion of the Calculation Agent, fairly represent the level of the AMEX Biotechnology Index or the Successor Index had those changes or
modifications not been made, then, from and after that time, the Calculation Agent will notify the Corporation and the Trustee. The Calculation Agent will make those calculations and adjustments as, in the good faith judgment of the Calculation
Agent, may be necessary in order to arrive at a level of a stock index comparable to the AMEX Biotechnology Index or the Successor Index, as the case may be, as if those changes or modifications had not been made, and calculate the closing levels
with reference to the AMEX Biotechnology Index or the Successor Index, as adjusted. Accordingly, if the method of calculating the AMEX Biotechnology Index or a Successor Index is modified so that the level of such index is a fraction of what it
would have been if it had not been modified (e.g., due to a split in the index), then the Calculation Agent shall adjust that index in order to arrive at a level of the AMEX Biotechnology Index or the Successor Index as if it had not been modified
(e.g., as if the split had not occurred). 
  

 12 

 Role of the Calculation Agent 
 The Calculation Agent has the sole discretion to make all determinations regarding this Note, including determinations regarding the Index Return, the Periodic Return, the Supplemental Redemption Amount, Market
Disruption Events, Successor Indices, and business days. Absent manifest error, all determinations of the Calculation Agent will be final and binding on the holder of this Note and the Corporation, without any liability on the part of the
Calculation Agent. 
 The Corporation has initially appointed its affiliate, Banc of America Securities LLC, as the Calculation Agent, but
the Corporation may change the Calculation Agent at any time without notifying the holder of this Note. 
  

 13Officer's Certificate of Determination

 Exhibit 4.1 
 BURLINGTON NORTHERN SANTA FE CORPORATION 
 Officers’ Certificate of Determination 
 Dated as of August 17, 2006 
 The
undersigned, Thomas N. Hund, Executive Vice President and Chief Financial Officer, and Jeffrey T. Williams, Senior General Attorney and Assistant Secretary, each of Burlington Northern Santa Fe Corporation, a Delaware corporation (the
“Company”), do hereby certify that pursuant to the authority granted in the resolutions (collectively, the “Resolutions”) of the Board of Directors of the Company adopted on December 8, 2005, and pursuant to Sections 201,
301 and 303 of the Indenture, dated as of December 1, 1995 (the “Indenture”), between the Company and J.P. Morgan Trust Company, National Association, as successor to The First National Bank of Chicago, as Trustee (the
“Trustee”), there was established as of August 17, 2006 a series of securities under the Indenture with the following terms: 
  

	 	1.	The securities are entitled “6.20% Debentures due August 15, 2036” (the “Debentures”). 

  

	 	2.	The Debentures are initially being offered in the aggregate principal amount of $300,000,000 (except for Debentures authenticated and delivered upon registration of transfer of, or
in exchange for, or in lieu of, other Debentures pursuant to Section 304, 305, 306, 906 or 1107 of the Indenture and any Debentures which pursuant to Section 303 are deemed never to have been authenticated and delivered thereunder). The
Company may, without the consent of the Holders, issue additional Debentures and thereby increase such principal amount, on the same terms and conditions and with the same CUSIP number as the Debentures. 

  

	 	3.	The principal amount of the Debentures will mature on August 15, 2036, subject to the provisions of the Indenture relating to acceleration. 

  

	 	4.	The Debentures will bear interest from August 17, 2006 or from the most recent Interest Payment Date (as defined below) to which interest has been paid or provided for, at the
rate of 6.20% per annum, payable semiannually in arrears on February 15 and August 15 of each year (each, an “Interest Payment Date”), commencing February 15, 2007 to the persons in whose names the Debentures are
registered on the close of business on the immediately preceding February 1 and August 1, respectively, whether or not such day is a Business Day (each, a “Regular Record Date”). 

  

	 	5.	 Subject to Section 9 below, the principal of and interest on the Debentures will be payable at the office or agency of the Company maintained for that purpose,
pursuant to the Indenture, in The City of New York, which shall be initially the corporate trust 

	 	 
office of the Trustee; provided, however, that at the option of the Company, such payment of interest may be made by check mailed to the person entitled
thereto as provided in the Indenture. 

  

	 	6.	The Debentures will be redeemable as a whole or in part at the option of the Company at a redemption price equal to the greater of (i) one hundred percent (100%) of the
principal amount of the Debentures to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date on a semiannual basis (assuming a 360-day year
consisting of twelve 30-day months) at the Treasury Rate (as defined below), plus 20 basis points, plus in either case accrued interest thereon to the date of redemption. 

 “Treasury Rate” means, with respect to any redemption date, the rate per annum equal to the semiannual equivalent yield to maturity of the
Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for such redemption date. 
 “Comparable Treasury Issue” means the United States Treasury security selected by an Independent Investment Banker as having a maturity
comparable to the remaining term of the Debentures to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the
remaining term of such Debentures. “Independent Investment Banker” means one of the Reference Treasury Dealers appointed by the Trustee after consultation with the Company. 
 “Comparable Treasury Price” means, with respect to any redemption date, (i) the average of the bid and asked prices for the Comparable
Treasury Issue (expressed in each case as a percentage of its principal amount) on the third business day preceding such redemption date, as set forth in the daily statistical release (or any successor release) published by the Federal Reserve Bank
of New York and designated “Composite 3:30 p.m. Quotations for U.S. Government Securities” or (ii) if such release (or any successor release) is not published or does not contain such prices on such business day, (A) the average
of the Reference Treasury Dealer Quotations for such redemption date, after excluding the highest and lowest such Reference Treasury Dealer Quotations, or (B) if the Trustee obtains fewer than four such Reference Treasury Dealer Quotations, the
average of all such quotations. 
 “Reference Treasury Dealer Quotations” means, with respect to each Reference Treasury Dealer and
any redemption date, the average, as determined by the Trustee, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Trustee by such Reference
Treasury Dealer at 5:00 p.m. on the third business day preceding such redemption date. 
  

 2 

 “Reference Treasury Dealer” means each of Barclays Capital Inc., Goldman, Sachs & Co.
and J.P. Morgan Securities Inc. and their respective successors; provided, however, that if any of the foregoing shall cease to be a primary U.S. Government securities dealer in New York City (a “Primary Treasury Dealer”), the Company
shall substitute therefor another Primary Treasury Dealer. 
 Notice of any redemption will be mailed at least 30 days but not more than 60
days before the redemption date to each holder of the Debentures to be redeemed. 
 Unless the Company defaults in payment of the redemption
price, on and after the redemption date interest will cease to accrue on the Debentures or portions thereof called for redemption. 
  

	 	7.	The Debentures shall not be entitled to the benefit of any sinking fund, nor shall the Debentures be repayable at the option of the registered Holders thereof.

  

	 	8.	Subject to paragraph 9 below, the Debentures shall be issued in denominations of $1,000 and integral multiples thereof. 

  

	 	9.	Upon issuance the Debentures will be represented by one or more Global Securities deposited with, or on behalf of, The Depository Trust Company (the “Depositary”).
Settlement for the Debentures will be made by the Underwriters (as hereinafter defined) in immediately available funds. All payments of principal and interest shall be made by the Company in immediately available funds as long as the Debentures are
represented by Global Securities. As long as the Debentures are represented by Global Securities registered in the name of the Depositary or its nominee, the Debentures will trade in the Depositary’s Same-Day Funds Settlement System, and
secondary market trading activity in the Debentures will therefore settle in immediately available funds. Except as set forth in the Indenture or in the Prospectus Supplement relating to the Debentures, the Debentures will not be issuable in
definitive form. 

 Furthermore, we hereby (i) approve the form of and authorize the execution and delivery of the
Debentures (a copy of which is attached as Exhibit A), the Underwriting Agreement, dated August 14, 2006, between the Company and Barclays Capital Inc., Goldman, Sachs & Co. and J.P. Morgan Securities Inc., as representatives of the
several underwriters listed therein (a copy of which is attached as Exhibit B) and (ii) ratify the execution and delivery of the Indenture (a copy of which is attached as Exhibit C). 
 All capitalized terms used herein and not otherwise defined shall have the meanings given such terms in the Indenture. 
 [Remainder of page intentionally left blank. Signature page follows.] 
  

 3 

 IN WITNESS WHEREOF, we have set our hands as of the date above first written. 
  

			
		
	By:	 	/s/ Thomas N. Hund
		 	 Thomas N. Hund
 Executive Vice President
and
 Chief Financial Officer

		
	By:	 	/s/ Jeffrey T. Williams
		 	 Jeffrey T. Williams
 Senior General Attorney
and
 Assistant Secretary

 EXHIBIT A 
 BURLINGTON NORTHERN SANTA FE CORPORATION 
 6.20% DEBENTURE DUE AUGUST 15, 2036 
  

			
	REGISTERED	  	$300,000,000.00
	No. R-1	  	CUSIP No. 12189TAX2

 THIS SECURITY IS A GLOBAL
SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND
IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF.
THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR
A SECURITY REGISTERED, AND NO TRANSFER OF THIS SECURITY IN WHOLE OR
IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER
THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED
CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 
 BURLINGTON
NORTHERN SANTA FE CORPORATION, a corporation duly organized and existing under the laws of Delaware (herein called the “Company”, which term includes any successor Person under the Indenture hereinafter referred to), for value received,
hereby promises to pay to CEDE & CO. or registered assigns, the principal sum of Three Hundred Million Dollars ($300,000,000.00) on August 15, 2036, and to pay interest thereon from August 17, 2006 or from the most recent Interest
Payment Date to which interest has been paid or duly provided for, semi-annually on February 15 and August 15 in each year, commencing February 15, 2007 at the rate of 6.20% per annum, until the principal hereof is paid or made
available for payment. The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in such Indenture, be paid to the Person in whose name this Security (or one or more Predecessor Securities) is
registered at the close of business on the Regular Record Date for such interest, which shall be the February 1 or August 1 (whether or not a Business Day), as the case may be, next preceding such Interest Payment Date. Any such interest
not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular Record Date and may either be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the
close of business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this series not less than 10 days prior to such Special Record Date, or
be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be required by such exchange, all as more fully
provided in said Indenture. 
 Payment of the principal of (and premium, if any) and interest on this Security will be made at the office or
agency of the Company maintained for that purpose in the Borough of Manhattan, The City of New York, in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts;
provided, however, that at the option of the Company payment of interest may be made by check mailed to the address of the Person entitled thereto as such address shall appear in the Security Register. 
 Reference is hereby made to the further provisions of this Security set forth on the reverse hereof, which further provisions shall for all purposes have
the same effect as if set forth at this place. 
 Unless the certificate of authentication hereon has been executed by the Trustee referred
to on the reverse hereof by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

 IN WITNESS WHEREOF, the Company has caused this instrument
to be duly executed under its corporate seal. 
  

									
	Dated: August __ , 2006	 		 	BURLINGTON NORTHERN SANTA FE CORPORATION
					
		 		 		 	 By
	 	  
		 		 		 		 	 Linda J. Hurt
 Assistant Vice President – Finance and Treasurer

  

	
	Attest:
	
	   
	 Jeffrey T. Williams
 Assistant Secretary

 This is one of the Securities of the series designated therein referred to in the within-mentioned
Indenture. 
  

									
	Dated: August __, 2006	 		 	 J.P. MORGAN TRUST COMPANY,
 NATIONAL
ASSOCIATION
 As Trustee

					
		 		 		 	 By
	 	  
		 		 		 		 	Authorized Officer

 [REVERSE OF DEBENTURE] 
 This Security is one of a duly authorized issue of securities of the Company (herein called the “Securities”), issued and to be issued in one or more series under an Indenture, dated as of December 1,
1995 (herein called the “Indenture”, which term shall have the meaning assigned to it in such instrument), between the Company and J.P. Morgan Trust Company, National Association, as successor to The First National Bank of Chicago, as
Trustee (herein called the “Trustee”, which term includes any successor trustee under the Indenture), and reference is hereby made to the Indenture for a statement of the respective rights, limitations of rights, duties and immunities
thereunder of the Company, the Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered. This Security is one of the series designated on the face hereof and will initially
be offered in the principal amount of $300,000,000. The Company may, without the consent of the Holders, issue additional Securities and thereby increase such principal amount in the future, on the same terms and conditions and with the same CUSIP
number as this Security. 
 The Securities of this series are subject to redemption upon not less than 30 and not more than 60 days’
notice by mail, at any time, as a whole or in part, at the election of the Company, at a redemption price equal to the greater of (i) 100% of their principal amount or (ii) the sum of the present values of the remaining scheduled payments
of principal and interest thereon discounted to the date of redemption on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined in the Officers’ Certificate establishing the Securities
of this series), plus 20 basis points, plus in either case accrued interest to the date of redemption. 
 In the event of redemption of this
Security in part only, a new Security or Securities of this series and of like tenor for the unredeemed portion hereof will be issued in the name of the Holder, upon the cancellation hereof. 
 The Indenture contains provisions for defeasance at any time of the entire indebtedness of this Security or certain restrictive covenants and Events of
Default with respect to this Security, in each case upon compliance with certain conditions set forth in the Indenture. 
 If an Event of
Default with respect to Securities of this series shall occur and be continuing, the principal of the Securities of this series may be declared due and payable in the manner and with the effect provided in the Indenture. 
 The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the
Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority in principal amount of the Securities at the time
Outstanding of each series to be affected. The Indenture also contains provisions permitting the Holders of specified percentages in principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all
Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences. Any such consent or waiver by the Holder of this Security shall be
conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is
made upon this Security. 
 Officers’ Certificate (Indenture) 

 As provided in and subject to the provisions of the Indenture, the Holder of this Security shall not have
the right to institute any proceeding with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy thereunder, unless such Holder shall have previously given the Trustee written notice of a continuing Event
of Default with respect to the Securities of this series, the Holders of not less than 25% in principal amount of the Securities of this series at the time Outstanding shall have made written request to the Trustee to institute proceedings in
respect of such Event of Default as Trustee and offered the Trustee reasonable indemnity, and the Trustee shall not have received from the Holders of a majority in principal amount of Securities of this series at the time Outstanding a direction
inconsistent with such request, and the Trustee shall have failed to institute any such proceeding, for 60 days after receipt of such notice, request and offer of indemnity. The foregoing shall not apply to any suit instituted by the Holder of this
Security for the enforcement of any payment of principal hereof or any premium or interest hereon on or after the respective due dates expressed herein. 
 No reference herein to the Indenture and no provision of this Security or of the Indenture shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of and any
premium and interest on this Security at the times, place and rate, and in the coin or currency, herein prescribed. 
 As provided in the
Indenture and subject to certain limitations therein set forth, the transfer of this Security is registrable in the Security Register, upon surrender of this Security for registration of transfer at the office or agency of the Company in any place
where the principal of and any premium and interest on this Security are payable, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof
or his attorney duly authorized in writing, and thereupon one or more new Securities of this series and of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or
transferees. 
 The Securities of this series are issuable only in registered form without coupons in denominations of $1,000 and any
integral multiple thereof. As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal amount of Securities of this series and of like tenor of a
different authorized denomination, as requested by the Holder surrendering the same. 
 No service charge shall be made for any such
registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. 
 Prior to due presentment of this Security for registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat
the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security is overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary. 
 All terms used in this Security which are defined in the Indenture shall have the meanings assigned to them in the Indenture. 
 Officers’ Certificate (Indenture)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}]]